Literature DB >> 24053576

Renal tumour nephrometry score does not correlate with the risk of radiofrequency ablation complications.

Casey A Seideman1, Jeffrey Gahan, Matthew Weaver, Ephrem O Olweny, Michael Richter, Danny Chan, Jeffrey A Cadeddu.   

Abstract

OBJECTIVES: To assess whether the R.E.N.A.L. nephrometry score (consists of [R]adius [tumour size as maximal diameter], [E]xophytic/endophytic properties of the tumour, [N]earness of tumour deepest portion to the collecting system or sinus, [A]nterior [a]/posterior [p] descriptor and the [L]ocation relative to the polar line) is associated with complication risk in patients that have radiofrequency ablation (RFA) for small renal masses (SRMs). To evaluate a standardised system for predicting complication risks which has not been studied. PATIENTS AND METHODS: We reviewed the records of all patients who underwent RFA at our institution between May 2001 and May 2011. RFA was performed using a temperature-based system and a 25-G nine-tine array needle probe. Patients with preoperative imaging available for R.E.N.A.L. nephrometry scoring were included. R.E.N.A.L. composite scores, tertile stratification and preoperative patient characteristics were analysed for significance in relation to complications. Complications were defined using the Clavien-Dindo classification system.
RESULTS: In all, 199 patients had preoperative R.E.N.A.L. nephrometry scores available; 170 underwent percutaneous RFA and 29 laparoscopic RFA. The mean (range) American Society of Anesthesiologists (ASA) score was 2.6 (1-4). The mean (range) tumour size was 2.4 (0.7-5.4) cm. Overall, 14 complications were identified; 10 minor (Clavien I-II) and four major (Clavien III-IV). There was no significant association between complications and R.E.N.A.L. nephrometry score, R.E.N.A.L. nephrometry tertiles, tumour diameter, tumour location or ASA score (P > 0.05).
CONCLUSION: R.E.N.A.L. nephrometry scoring fails to predict complications of RFA for SRMs when using a temperature-based nine-tine array probe.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  RENAL nephrometry score; carcinoma; complications; radiofrequency ablation; renal cell

Mesh:

Year:  2013        PMID: 24053576     DOI: 10.1111/bju.12276

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Microwave ablation of malignant renal tumours: intermediate-term results and usefulness of RENAL and mRENAL scores for predicting outcomes and complications.

Authors:  Anna Maria Ierardi; Alessio Puliti; Salvatore Alessio Angileri; Mario Petrillo; Ejona Duka; Chiara Floridi; Michela Lecchi; Gianpaolo Carrafiello
Journal:  Med Oncol       Date:  2017-04-19       Impact factor: 3.064

Review 2.  Ablative Therapies for the Treatment of Small Renal Masses: a Review of Different Modalities and Outcomes.

Authors:  Nicholas Kavoussi; Noah Canvasser; Jeffrey Caddedu
Journal:  Curr Urol Rep       Date:  2016-08       Impact factor: 3.092

3.  A simplified new-generation renal mass complexity scoring system.

Authors:  Ali Hajiran; Ahmet M Aydin; Salim K Cheriyan; Wade J Sexton
Journal:  Ann Transl Med       Date:  2019-09

Review 4.  Renal Cell Carcinoma Ablation: Preprocedural, Intraprocedural, and Postprocedural Imaging.

Authors:  Winston B Joe; Jessica G Zarzour; Andrew J Gunn
Journal:  Radiol Imaging Cancer       Date:  2019-11-29

5.  Clinical efficacy of bipolar radiofrequency ablation of small renal masses.

Authors:  S G C Kroeze; M Agenant; G N Jonges; T Stein; J L H R Bosch
Journal:  World J Urol       Date:  2014-10-29       Impact factor: 4.226

Review 6.  Image-guided ablation of primary liver and renal tumours.

Authors:  David J Breen; Riccardo Lencioni
Journal:  Nat Rev Clin Oncol       Date:  2015-01-20       Impact factor: 66.675

7.  Association among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation.

Authors:  Cristian Konstantinidis; Enrique Trilla; Xavier Serres; Carolina Montealegre; David Lorente; Rafael Castellón; Juan Morote
Journal:  Cent European J Urol       Date:  2019-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.